Al Medwar, former head of marketing for the oncology group at Merck subsidiary EMD Pharmaceuticals, is the new vice president of marketing for BioDelivery Sciences International.

Medwar begins his new duties on April 16. He joins BDSI as the firm prepares to release data on the Phase III clinical trial of its lead drug candidate called BEMA Fentanyl.

The drug is intended to serve as a treatment for breakthrough cancer pain.

Before joining EMD, Medwar was director of marketing for Triangle Pharmaceuticals. He also has worked at Glaxxo Wellcome. He is a graduate of Cornell University and earned an MBA at Bentley College.